Beijing Tiantan Biological Products Co., Ltd. (600161.SS) Bundle
Curious who's quietly positioning around Beijing Tiantan Biological Products Co., Ltd. (600161.SS)? Major holders include BlackRock's iShares Core MSCI Emerging Markets ETF with 870,400 shares (as of Feb 28, 2025) and the KraneShares ICBCCS S&P China 500 UCITS ETF with 8,800 shares (as of Mar 31, 2024), while the company's ties to China National Biotec Group/Sinopharm point to potential state-aligned ownership; investors are also eyeing its on-the-ground footprint of 107 plasmapheresis centers across 16 provinces, a 20% domestic market share in 2023, and financial momentum after a 16.44% revenue increase to ¥6.03 billion in 2024-all factors that shape institutional interest and prompt questions about market impact, shareholder composition and strategic motives driving buying patterns.
Beijing Tiantan Biological Products Co., Ltd. (600161.SS) - Who Invests in Beijing Tiantan Biological Products Co., Ltd. and Why?
Beijing Tiantan Biological Products Co., Ltd. (600161.SS) attracts a mix of passive ETF holders, state-affiliated investors, domestic institutions and retail investors. Key ownership and investor themes reflect exposure to China's healthcare growth, strategic state interest in blood products, and solid recent financial performance.- ETF/Index investors: passive funds seeking broad China or emerging-market healthcare exposure.
- State-held/strategic investors: affiliation with China National Biotec Group (a Sinopharm subsidiary) implies meaningful state-aligned stakes.
- Domestic institutional investors: pension, insurance and asset managers targeting stable cash-flow healthcare franchises.
- Retail and specialist healthcare investors: attracted by market leadership in blood products and plasma collection footprint.
| Investor | Date | Holding (shares) | Notes |
|---|---|---|---|
| Kraneshares ICBCCS S&P China 500 UCITS ETF | Mar 31, 2024 | 8,800 | ≈0.09% of ETF net assets (exposure via China 500 index) |
| BlackRock iShares Core MSCI Emerging Markets ETF | Feb 28, 2025 | 870,400 | Part of diversified EM healthcare exposure |
| China National Biotec Group / Sinopharm (affiliated) | Ongoing | Significant strategic stake (state-affiliated) | Aligns company with national biopharma priorities |
- Operational footprint: 107 plasmapheresis centers across 16 provinces - improves plasma supply reliability and appeals to investors focused on scalable collection networks.
- Market position: ~20% domestic blood-products market share in 2023 - signals leadership and pricing/volume advantages.
- Recent financial momentum: revenue up 16.44% to ¥6.03 billion in 2024 - attracts growth- and value-seeking investors.
- Regulatory and strategic appeal: biotech critical to public health; state ties reduce some political/regulatory risk for domestic investors.
Beijing Tiantan Biological Products Co., Ltd. (600161.SS) - Institutional Ownership and Major Shareholders of Beijing Tiantan Biological Products Co., Ltd.
Beijing Tiantan Biological Products Co., Ltd. displays a mix of state-affiliated ownership, institutional ETF holdings, and specialized healthcare investors. The shareholder base reflects strategic national interest in biopharma, passive index exposure via large ETFs, and domestic operational strength (plasmapheresis network and blood-products market position) that attracts sector-focused investors.| Shareholder / Holder | Date (reporting) | Holding (shares) | Notes |
|---|---|---|---|
| Kraneshares ICBCCS S&P China 500 UCITS ETF | Mar 31, 2024 | 8,800 | Represents ~0.09% of the ETF's net assets (small position within China 500 exposure) |
| BlackRock - iShares Core MSCI Emerging Markets ETF (IEMG or similar) | Feb 28, 2025 | 870,400 | Passive EM exposure; sizeable shareholding within a diversified emerging-markets portfolio |
| China National Biotec Group / Sinopharm (state-affiliated) | Ongoing | Significant stake (varies by filings) | Strategic state-owned affiliation aligning company with national biopharma policy |
- Domestic operational footprint: 107 plasmapheresis centers across 16 provinces - supports stable supply chain and recurring revenue streams.
- Market leadership: ~20% share of China's blood products market in 2023 - a key draw for investors seeking market-dominant names.
- Recent financial performance: revenue up 16.44% to ¥6.03 billion in 2024 - signals demand growth and improved top-line momentum.
- Investor types observed: state-owned enterprises, global passive ETFs, healthcare-focused funds, and domestic institutional investors.
- State alignment: Sinopharm affiliation can mean preferential policy positioning, procurement advantage, and potential stability from state-backed ownership.
- ETF inclusion: Holdings by large ETFs (e.g., BlackRock, Kraneshares) provide liquidity and index-driven demand but can also cause passive-flow volatility on rebalances.
- Operational moat: Plasmapheresis center network and 20% market share support predictable earnings and cash flow visibility attractive to yield- or quality-seeking investors.
- Growth signal: 16.44% revenue growth to ¥6.03 billion (2024) reinforces appeal to growth-oriented institutions and EM healthcare allocations.
Beijing Tiantan Biological Products Co., Ltd. (600161.SS) - Key Investors and Their Impact on Beijing Tiantan Biological Products Co., Ltd.
Ownership and institutional backing shape both market perception and strategic options for Beijing Tiantan Biological Products Co., Ltd. Below are the principal investor footprints, their scale, timing, and likely motivations.
| Investor | Reporting Date | Shares Held | Notes / Impact |
|---|---|---|---|
| KraneShares ICBCCS S&P China 500 UCITS ETF | March 31, 2024 | 8,800 | Holding represented ≈0.09% of the ETF's net assets; passive index exposure increases liquidity and overseas retail visibility. |
| BlackRock - iShares Core MSCI Emerging Markets ETF | February 28, 2025 | 870,400 | Large passive EM allocation; contributes to stable, diversified institutional demand and potential inclusion in EM index rebalances. |
| China National Biotec Group Limited (Sinopharm subsidiary) | Ongoing / strategic | Not publicly quantified here | State-affiliated ownership aligns company with national public-health priorities and may facilitate regulatory support, procurement channels, and R&D partnerships. |
- Scale & liquidity: ETF ownership (KraneShares, iShares) creates steady passive flows and improves free-float turnover.
- Strategic alignment: State-owned affiliation delivers preferential positioning in domestic vaccine and blood-product procurement.
- Operational footprint: 107 plasmapheresis centers across 16 provinces bolster supply stability, regional reach, and investor confidence in volume growth.
Financial and market metrics that drive investor interest:
| Metric | Value / Year |
|---|---|
| Revenue | ¥6.03 billion (2024) - +16.44% YoY |
| Domestic blood products market share | ~20% (2023) |
| Plasmapheresis centers | 107 centers across 16 provinces |
- Growth signal: 16.44% revenue growth to ¥6.03bn in 2024 attracts growth-oriented and sector-focused investors.
- Market leadership: ~20% domestic market share supports defensive positioning for income-focused and long-term institutional holders.
- Network effects: Wide plasmapheresis network reduces supply risk and supports margin sustainability-important for valuation premiums.
- Policy sensitivity: State-linked ownership can dampen takeover risk while increasing exposure to government procurement cycles and pricing policies.
For investors, the combined profile-passive ETF allocations providing liquidity, large institutional holdings offering stability, and state-affiliated strategic ties delivering market access-forms the basis of conviction for different investor types (passive indexers, EM/healthcare funds, and domestically oriented strategic investors). Explore company strategic positioning and values here: Mission Statement, Vision, & Core Values (2026) of Beijing Tiantan Biological Products Co., Ltd.
Beijing Tiantan Biological Products Co., Ltd. (600161.SS) - Market Impact and Investor Sentiment
Beijing Tiantan Biological Products Co., Ltd. (600161.SS) sits at the intersection of state-aligned healthcare policy and growing private/institutional investor interest. Recent holdings and operational metrics point to a company that is both strategically important and financially attractive to a range of investors.- Institutional holdings: Kraneshares ICBCCS S&P China 500 UCITS ETF reported 8,800 shares as of March 31, 2024, representing ~0.09% of that ETF's net assets; BlackRock's iShares Core MSCI Emerging Markets ETF held 870,400 shares as of February 28, 2025.
- State linkage: Affiliation with China National Biotec Group Limited (a Sinopharm subsidiary) implies potential meaningful state-owned ownership and policy alignment, which can stabilize investor sentiment but also raise governance/watchlist considerations.
- Operational footprint: 107 plasmapheresis centers across 16 provinces provide a broad domestic network that supports recurring plasma-derived product volumes and revenue visibility.
- Financial momentum: Revenue grew 16.44% year-over-year to ¥6.03 billion in 2024, signaling accelerating top-line performance that attracts growth- and value-oriented investors.
- Market position: Estimated 20% share of China's blood products market in 2023, marking the company as a leading domestic player with scale advantages.
| Metric | Value / Date |
|---|---|
| Kraneshares ICBCCS S&P China 500 UCITS ETF holding | 8,800 shares (Mar 31, 2024); ~0.09% of ETF net assets |
| iShares Core MSCI Emerging Markets ETF holding | 870,400 shares (Feb 28, 2025) |
| Affiliation | China National Biotec Group Limited (Sinopharm subsidiary) |
| Plasmapheresis centers | 107 centers across 16 provinces |
| 2024 Revenue | ¥6.03 billion (up 16.44% YoY) |
| Domestic market share (blood products) | ~20% (2023) |
- Why investors buy: stable revenue growth (16.44% in 2024), leading market share (20% in 2023), wide plasma collection network (107 centers), and perceived strategic backing via Sinopharm affiliation.
- Risks investors weigh: government/shareholder influence given state ties, regulatory oversight in blood products, plasma supply volatility, and margin pressure from pricing/regulatory changes.
- Investor profiles likely involved: passive EM/China ETFs (e.g., iShares, KraneShares), domestic institutional investors aligned with national healthcare priorities, and specialized healthcare/biotech funds seeking exposure to plasma-derived therapeutics.
Beijing Tiantan Biological Products Co., Ltd. (600161.SS) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.